ACM
AEON icon

Atalaya Capital Management’s AEON Biopharma AEON Stock Holding History

Atalaya Capital Management’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$3.28M Hold
51,042
– – 7.29% 5
2024
Q1 		$36.2M Hold
51,042
– – 42.59% 1
2023
Q4 		$22.6M Hold
51,042
– – 32.55% 1
2023
Q3 		$19.8M Buy
+51,042
New +$23.4M 22.08% 1

Other funds holding AEON

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Atalaya Capital Management's AEON Position: Q2 2024 in Review

Atalaya Capital Management held its AEON Biopharma (AEON) position steady in Q2 2024 at 51,042 shares worth $3.28M. The position accounts for 7.29% of the portfolio, ranked #5.

Atalaya Capital Management first reported a position in AEON in Q3 2023 and has held it in 4 quarters since. The position peaked at $36.2M in Q1 2024. 24 funds tracked by Wall St. Rank hold AEON as of Q2 2024.

  • Atalaya Capital Management held 51,042 shares of AEON Biopharma worth $3.28M as of Q2 2024.
  • Atalaya Capital Management left its AEON Biopharma share count unchanged in Q2 2024.
  • AEON Biopharma made up 7.29% of Atalaya Capital Management's portfolio in Q2 2024, its #5 holding.
  • Atalaya Capital Management first reported a position in AEON Biopharma in Q3 2023 and has held it in 4 quarters since.
  • Atalaya Capital Management's AEON Biopharma position peaked at $36.2M in Q1 2024.
  • 24 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2024.

Based on Atalaya Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.